J. Harry and . Buncke, Université d'Helsinki (FINLANDE) Professeur Paul MICHIELSEN (1979) Université Catholique, Canada) Professeur James STEICHEN, 1989.

P. Charles and A. Berry, Centre Universitaire d'Hô Chi Minh-Ville (VIÊTNAM) Professeur Pierre-Marie GALETTI (1982) Brown University, Massachusetts Institute of Technology (U.S.A) Professeur Maria DELIVORIA-PAPADOPOULOS, 1982.

R. Facteurs-de-risque-d-'iu-chez-les-patients-avec-une, Tableau 3), p.59

V. , R. 1. Peyrin-biroulet, L. Loftus, E. , J. Colombel et al., The natural history of adult Crohn's disease in population-based cohorts, Am J Gastroenterol, vol.105, pp.289-97, 2009.

R. Modigliani, J. Mary, J. Simon, A. Cortot, J. Soule et al., Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Gastroenterology, vol.98, issue.4, pp.811-819, 1990.
DOI : 10.1016/0016-5085(90)90002-I

J. Cosnes, I. Nion-larmurier, L. Beaugerie, P. Afchain, E. Tiret et al., Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, Gut, vol.54, issue.2, pp.237-278, 2005.
DOI : 10.1136/gut.2004.045294

B. Feagan, R. Fedorak, E. Irvine, G. Wild, L. Sutherland et al., A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease, New England Journal of Medicine, vol.342, issue.22, pp.1627-1659, 2000.
DOI : 10.1056/NEJM200006013422202

S. Hanauer, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

J. Colombel, E. Loftus, J. Tremaine, W. Egan, L. Harmsen et al., The safety profile of infliximab in patients with Crohn???s disease: The Mayo Clinic experience in 500 patients, Gastroenterology, vol.126, issue.1, pp.19-31, 2004.
DOI : 10.1053/j.gastro.2003.10.047

N. Viget, G. Vernier-massouille, D. Salmon-ceron, Y. Yazdanpanah, and J. Colombel, Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis, Gut, vol.57, issue.4, pp.549-58, 2008.
DOI : 10.1136/gut.2006.114660

B. Foxman, The epidemiology of urinary tract infection, Nature Reviews Urology, vol.8, issue.12, pp.653-60, 2010.
DOI : 10.3201/eid1307.070094

C. Solem, E. Loftus, J. Tremaine, W. Pemberton, J. Wolff et al., Fistulas to the urinary system in Crohn's disease: clinical features and outcomes, The American Journal of Gastroenterology, vol.114, issue.9, pp.2300-2305, 2002.
DOI : 10.1056/NEJM199905063401804

T. Jess, E. Loftus, J. Harmsen, W. Zinsmeister, A. Tremaine et al., Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Gut, vol.55, pp.1940-20041248, 2006.

D. Duricova, N. Pedersen, M. Elkjaer, M. Gamborg, P. Munkholm et al., Overall and cause-specific mortality in Crohn??s disease: A meta-analysis of population-based studies, Inflammatory Bowel Diseases, vol.309, issue.2, pp.347-53, 2010.
DOI : 10.1126/science.1114233

H. Ben-ami, Y. Ginesin, D. Behar, D. Fischer, Y. Edoute et al., Diagnosis and Treatment of Urinary Tract Complication in Crohn???s Disease: An Experience over 15 Years, Canadian Journal of Gastroenterology, vol.16, issue.4, pp.225-234, 2002.
DOI : 10.1155/2002/204614

J. Kyle, Urinary complications of Crohn's disease, World Journal of Surgery, vol.56, issue.2, pp.153-60, 1980.
DOI : 10.1148/121.1.75

G. Schmiemann, E. Kniehl, K. Gebhardt, and M. Matejczyk, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review, Dtsch Arztebl Int, vol.107, pp.361-368, 2010.

A. Khan, A. Piris, J. Truelove, and S. , An experiment to determine the active therapeutic moiety of sulphasalazine Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease, Lancet Drugs, vol.241, issue.17, pp.892-5647, 1977.

P. Marteau and C. Cellier, Side effects of 5-aminosalicylic acid], Gastroenterol Clin Biol, vol.21, pp.377-86, 1997.

H. Kotanagi, M. Ito, K. Koyama, and M. Chiba, Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease, Journal of Gastroenterology, vol.33, issue.4, pp.571-575, 1998.
DOI : 10.1007/s005350050135

Z. Abboudi, J. Marsh, G. Smith-laing, and E. Gordon-smith, Fatal aplastic anaemia after mesalazine Casellas F, Vallano A, Malagelada JR. Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories, Lancet J Clin Gastroenterol, vol.34322, pp.542-21160, 1994.

I. Adcock, Molecular Mechanisms of Glucocorticosteroid Actions, Pulmonary Pharmacology & Therapeutics, vol.13, issue.3, pp.115-141, 2000.
DOI : 10.1006/pupt.2000.0243

P. Hench and E. Kendall, The effect of a hormone of the adrenal cortex (17-hydroxy-11- dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis, Mayo Clin Proc, vol.24, pp.181-97, 1949.

H. Malchow, K. Ewe, J. Brandes, H. Goebell, H. Ehms et al., European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment, Gastroenterology, vol.86, pp.249-66, 1984.

G. Hyde and D. Jewell, The management of severe ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.11, issue.3, pp.419-443, 1997.
DOI : 10.1046/j.1365-2036.1997.00187.x

S. Plevy, Corticosteroid-sparing treatments in patients with Crohn's disease, The American Journal of Gastroenterology, vol.39, issue.2, pp.1607-1624, 2002.
DOI : 10.1016/S0140-6736(97)80083-9

J. Marehbian, H. Arrighi, S. Hass, H. Tian, and W. Sandborn, Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease, The American Journal of Gastroenterology, vol.33, issue.10, pp.2524-2557, 2009.
DOI : 10.1111/j.1572-0241.2008.01960.x

A. Agrawal, S. Durrani, K. Leiper, A. Ellis, A. Morris et al., Effect of Systemic Corticosteroid Therapy on Risk for Intra-Abdominal or Pelvic Abscess in Non-operated Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.3, issue.12, pp.1215-1235, 2005.
DOI : 10.1016/S1542-3565(05)00759-7

G. Lichtenstein, B. Feagan, R. Cohen, B. Salzberg, R. Diamond et al., Serious Infections and Mortality in Association With Therapies for Crohn???s Disease: TREAT Registry, Clinical Gastroenterology and Hepatology, vol.4, issue.5, pp.621-651, 2006.
DOI : 10.1016/j.cgh.2006.03.002

M. Toruner, E. Loftus, J. Harmsen, W. Zinsmeister, A. Orenstein et al., Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease, Gastroenterology, vol.134, issue.4, pp.929-965, 2008.
DOI : 10.1053/j.gastro.2008.01.012

S. Schneeweiss, J. Korzenik, D. Solomon, C. Canning, J. Lee et al., Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections, Alimentary Pharmacology & Therapeutics, vol.58, issue.3, pp.253-64, 2009.
DOI : 10.7326/0003-4819-137-8-200210150-00015

P. Rutgeerts, R. Lofberg, H. Malchow, C. Lamers, G. Olaison et al., A Comparison of Budesonide with Prednisolone for Active Crohn's Disease, New England Journal of Medicine, vol.331, issue.13, pp.842-847, 1994.
DOI : 10.1056/NEJM199409293311304

S. Kane, P. Schoenfeld, W. Sandborn, W. Tremaine, T. Hofer et al., Systematic review: the effectiveness of budesonide therapy for Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.120, issue.6, pp.1509-1526, 2002.
DOI : 10.1016/S0016-5085(08)82247-0

Z. Smolenska, Z. Kaznowska, D. Zarowny, H. Simmonds, and R. Smolenski, Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis, Rheumatology, vol.38, issue.10, pp.997-1002, 1999.
DOI : 10.1007/978-1-4615-5381-6_3

M. Carter, A. Lobo, and S. Travis, Guidelines for the management of inflammatory bowel disease in adults, Gut, vol.53, issue.suppl_5, pp.1-16, 2004.
DOI : 10.1136/gut.2004.043372

A. Alfadhli, J. Mcdonald, B. Feagan, B. Feagan, J. Rochon et al., Methotrexate for induction of remission in refractory Crohn's disease Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators Infections during low-dose methotrexate treatment in rheumatoid arthritis, Cochrane Database Syst Rev N Engl J Med Boerbooms AM, Kerstens PJ Semin Arthritis Rheum, vol.2533224, issue.39, pp.3459-38292, 1995.

S. Sahasranaman, D. Howard, and S. Roy, Clinical pharmacology and pharmacogenetics of thiopurines, European Journal of Clinical Pharmacology, vol.20, issue.4, pp.753-67, 2008.
DOI : 10.7326/0003-4819-111-8-641

M. Dubinsky, Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety, Clinical Gastroenterology and Hepatology, vol.2, issue.9, pp.731-774, 2004.
DOI : 10.1016/S1542-3565(04)00344-1

J. Gisbert and F. Gomollon, Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review, The American Journal of Gastroenterology, vol.33, issue.Suppl 1, pp.1783-800, 2008.
DOI : 10.1155/2005/470863

W. Connell, M. Kamm, M. Dickson, A. Balkwill, J. Ritchie et al., Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease, The Lancet, vol.343, issue.8908, pp.1249-52, 1994.
DOI : 10.1016/S0140-6736(94)92150-4

L. Beaugerie, N. Brousse, A. Bouvier, J. Colombel, M. Lemann et al., Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, The Lancet, vol.374, issue.9701, pp.1617-1642, 2009.
DOI : 10.1016/S0140-6736(09)61302-7

URL : https://hal.archives-ouvertes.fr/hal-00466312

L. Peyrin-biroulet, P. Deltenre, N. De-suray, J. Branche, W. Sandborn et al., Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008.
DOI : 10.1016/j.cgh.2008.03.014

S. Targan, S. Hanauer, S. Van-deventer, L. Mayer, D. Present et al., A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997.
DOI : 10.1056/NEJM199710093371502

S. Hanauer, W. Sandborn, P. Rutgeerts, R. Fedorak, M. Lukas et al., Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Certolizumab pegol for the treatment of Crohn's disease, Gastroenterology N Engl J Med, vol.130357, pp.323-33228, 2006.

S. Schreiber, M. Khaliq-kareemi, I. Lawrance, O. Thomsen, S. Hanauer et al., Maintenance therapy with certolizumab pegol for Crohn's disease Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med N Engl J Med, vol.357340, issue.51, pp.239-501398, 1999.

J. Colombel, W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer et al., Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007.
DOI : 10.1053/j.gastro.2006.11.041

D. Rampton, Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy, Gut, vol.54, issue.10, pp.1360-1362, 2005.
DOI : 10.1136/gut.2005.076034

F. Tubach, D. Salmon-ceron, P. Ravaud, and M. X. , The RATIO observatory: French registry of??opportunistic infections, severe bacterial infections, and??lymphomas complicating anti-TnF?? therapy, Joint Bone Spine, vol.72, issue.6, pp.456-60, 2005.
DOI : 10.1016/j.jbspin.2005.10.004

J. Curtis, N. Patkar, A. Xie, C. Martin, J. Allison et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor ?? antagonists, Arthritis & Rheumatism, vol.149, issue.4, pp.1125-1158, 2007.
DOI : 10.1093/oxfordjournals.aje.a009758

F. Tubach, P. Ravaud, D. Salmon-ceron, N. Petitpain, O. Brocq et al., Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor-?? Antagonists, Clinical Infectious Diseases, vol.97, issue.1, pp.95-100, 2006.
DOI : 10.1046/j.1525-1373.2000.22420.x

A. Hofmann, Y. Beaulieu, F. Bernard, and P. Rico, Fulminant Legionellosis in Two Patients Treated with Infliximab for Crohn???s Disease: Case Series and Literature Review, Canadian Journal of Gastroenterology, vol.23, issue.12, pp.829-862, 2009.
DOI : 10.1155/2009/836938

L. Arrouy, F. Benhamou, A. Dray, J. Grenet, L. Corre et al., 59 Réseau d'alerte, d'Investigation et de surveillance des Infections Nosocomiales Enquête nationale de prévalence 2006 des infections nosocomiales, mai-juin 2006 Protocole national. 2006 [cited; Available from: http://www.invs.sante.fr/publications Epidémiologie des infections urinaires communautaires de l'adulte en France, AFSSAPS. Recommandation de bonne pratique Diagnostic et Antibiothérapie des infections urinaires bactériennes communautaires chez l'adulte In Les infections urinairesThe relationship between inflammatory bowel disease (IBD) and complications of urinary and male genital tracts, pp.677-83, 2006.

D. Schwartz, E. Loftus, J. Tremaine, W. Panaccione, R. Harmsen et al., The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota, Gastroenterology, vol.122, issue.4, pp.875-80, 2002.
DOI : 10.1053/gast.2002.32362

D. Present, Urinary tract fistulas in Crohn's disease: surgery versus medical therapy, The American Journal of Gastroenterology, vol.39, issue.9, pp.2165-2172, 2002.
DOI : 10.1016/0002-9610(84)90202-2

L. Peyrin-biroulet, A. Oussalah, N. Williet, C. Pillot, L. Bresler et al., Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease, Gut, vol.60, issue.7, pp.930-936, 2011.
DOI : 10.1136/gut.2010.227884

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

W. Hall, R. Ramachandran, S. Narayan, A. Jani, and S. Vijayakumar, An electronic application for rapidly calculating Charlson comorbidity score, BMC Cancer, vol.16, issue.1, p.94, 2004.
DOI : 10.1200/JCO.1998.16.4.1582

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-4-94?site=bmccancer.biomedcentral.com

E. Delong, D. Delong, and D. Clarke-pearson, Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-882, 1988.
DOI : 10.2307/2531595

E. Boyko, S. Fihn, D. Scholes, L. Abraham, and B. Monsey, Risk of Urinary Tract Infection and Asymptomatic Bacteriuria among Diabetic and Nondiabetic Postmenopausal Women, American Journal of Epidemiology, vol.15, issue.7, pp.557-64, 2005.
DOI : 10.2337/diacare.15.7.815

F. Caron, Prise en charge des infections urinaires communautaires de l???adulte??: ce qui a chang??. ?? propos des recommandations??2008 de l???Agence fran??aise de s??curit?? sanitaire des produits de sant?? (Afssaps), La Presse M??dicale, vol.39, issue.1, pp.42-50, 2009.
DOI : 10.1016/j.lpm.2009.06.007

A. Peleg and D. Hooper, Hospital-Acquired Infections Due to Gram-Negative Bacteria, New England Journal of Medicine, vol.362, issue.19, pp.1804-1817, 2010.
DOI : 10.1056/NEJMra0904124

P. Sedman, J. Macfie, P. Sagar, C. Mitchell, J. May et al., The prevalence of gut translocation in humans, Gastroenterology, vol.107, issue.3, pp.643-652, 1994.
DOI : 10.1016/0016-5085(94)90110-4

E. Ozbek, Y. Ilbey, M. Cekmen, A. Simsek, M. Tekerekoglu et al., Bacterial translocation to kidney in rats with intestinal obstruction and the role of nitric oxide, Arch Ital Urol Androl, vol.81, pp.56-64, 2009.